Pharma Globenewswire

FDA Approves Agios’ AQVESME (mitapivat) as First Oral Therapy for Thalassemia: A Watershed Moment for Anemia Management

21 January 2026

The Food and Drug Administration (FDA) has granted approval to AQVESME (mitapivat), marking a historic milestone in the thalassemia treatment. As the first oral therapy indicated for adults with both non-transfusion-dependent (NTD) and transfusion-dependent (TD) alpha- or beta-thalassemia, this approval represents a

Market Insights·News·Reports

Chronic Refractory Cough Market Hits $8.5B in 2024!

21 January 2026

The chronic refractory cough (CRC) market is projected to witness substantial growth through 2034, driven by an expanding diagnosed patient population, increasing recognition of chronic cough as a distinct clinical condition, and the shortcomings of currently used off-label therapies. Chronic Refractory Cough

Chemotherapy-Induced Peripheral Neuropathy Market

Uncategorised

CIPN Market Size was around USD 1,500 million in 2023

21 January 2026

The chemotherapy-induced peripheral neuropathy (CIPN) treatment market is emerging as a high-growth, high-value opportunity, fueled by a profound lack of approved therapies and a substantial unmet clinical need. As the global use of chemotherapy particularly neurotoxic agents continues to rise, the number

Market Insights·News·Reports

Geographic Atrophy Market Poised for Robust Growth

21 January 2026

The global Geographic Atrophy Market is expected to witness substantial growth over the forecast period from 2025 to 2034, fueled by a rising elderly population, increasing disease prevalence, growing demand for disease-modifying treatments, and the advancement of novel therapeutic approaches—particularly complement inhibitor

Market Insights

Sickle Cell Disease Market Set for Robust Expansion at a CAGR of 22.1% (2025–2034) Across 6MM, Driven by Rising Prevalence and Breakthrough Gene Therapies

20 January 2026

The Sickle Cell Disease (SCD) market is projected to experience remarkable growth through 2034, supported by increasing disease prevalence, improving diagnostic awareness, and rapid advancements in disease-modifying and gene-based therapies. According to DelveInsight, the market is expected to expand at a CAGR

Clinical Trials

Lantern Pharma’s LP-284 Achieves Third FDA Orphan Drug Designation for Soft Tissue Sarcomas

20 January 2026

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage artificial intelligence-driven biopharmaceutical company pioneering synthetic lethal approaches to oncology, announced that the Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to LP-284 for the treatment of soft tissue sarcomas. This marks

Clinical Trials

Novartis Ianalumab Receives FDA Breakthrough Therapy Designation for Sjögren’s Disease: First Targeted BAFF-R Blocking B-Cell Depleter Demonstrates Statistically Significant Disease Activity Reduction; Regulatory Submissions Planned Q1 2026

16 January 2026

NEPTUNUS-1 and NEPTUNUS-2 met primary endpoints with clinically meaningful improvements in ESSDAI and patient-reported outcomes across 779 globally enrolled patients; ianalumab positioned to become first approved targeted treatment for second most prevalent rheumatic autoimmune disease Novartis announced that the U.S. Food and

Clinical Trials

GSK’s Bepirovirsen Demonstrates Statistically Significant Functional Cure Rates in Chronic Hepatitis B

16 January 2026

GlaxoSmithKline plc announced positive results from the B-Well 1 and B-Well 2 pivotal Phase III clinical trials evaluating bepirovirsen (GSK3228836), an investigational antisense oligonucleotide (ASO) designed as the first-in-class finite-duration therapy capable of achieving functional cure in patients with chronic hepatitis B

Drug Launches & Approvals

FDA Approves ZYCUBO (Copper Histidinate): First-Ever Treatment for Menkes Disease

15 January 2026

Sentynl Therapeutics, a US-based biopharmaceutical subsidiary of Zydus Lifesciences Limited, has achieved a landmark regulatory milestone with FDA approval of ZYCUBO (copper histidinate) injection for the treatment of pediatric patients with Menkes disease. This marks the first and only FDA-approved therapy for

Latest

FDA Approves Agios’ AQVESME (mitapivat) as First Oral Therapy for Thalassemia: A Watershed Moment for Anemia Management

Chronic Refractory Cough Market Hits $8.5B in 2024!

CIPN Market Size was around USD 1,500 million in 2023

Geographic Atrophy Market Poised for Robust Growth

Sickle Cell Disease Market Set for Robust Expansion at a CAGR of 22.1% (2025–2034) Across 6MM, Driven by Rising Prevalence and Breakthrough Gene Therapies

Lantern Pharma’s LP-284 Achieves Third FDA Orphan Drug Designation for Soft Tissue Sarcomas

Novartis Ianalumab Receives FDA Breakthrough Therapy Designation for Sjögren’s Disease: First Targeted BAFF-R Blocking B-Cell Depleter Demonstrates Statistically Significant Disease Activity Reduction; Regulatory Submissions Planned Q1 2026

GSK’s Bepirovirsen Demonstrates Statistically Significant Functional Cure Rates in Chronic Hepatitis B

FDA Approves ZYCUBO (Copper Histidinate): First-Ever Treatment for Menkes Disease

Recent Posts

Banner

Newsletter

Authors